ArticleAmerican journal of translational research2025
Xianling Gubao capsules improve oral health, alveolar bone defects, and bone density in patients with periodontitis.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multi-omics integration to identify immune-associated biomarkers and potential therapeutics in periodontitis.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the effects of Xianling Gubao Capsules (XGC) on alveolar bone and inflammatory mediators in the gingival crevicular fluid in patients with periodontitis.
methodsA retrospective analysis was conducted on 90 periodontitis patients who received medication treatment at Daqing Longnan Hospital from September 2022 to June 2023. Patients were categorized into three groups: a control group (n=30, receiving basic periodontal treatment), a Caltrate group (n=30, receiving basic treatment plus Caltrate), and an XGC group (n=30, receiving basic treatment plus Xianling Gubao Capsules). Changes in alveolar bone defect height, alveolar bone density, plaque index (PI), probing depth (PD), gingival index (GI), gingival crevicular fluid volume, and inflammatory mediator levels were compared before and after treatment.
resultsAfter 3 and 6 months of treatment, the XGC group exhibited significantly reduced alveolar bone defect height in incisors, canines, premolars, and molars and significantly increased alveolar bone density compared with the other two groups (all P<0.05). The XGC group also exhibited lower tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) levels and higher interleukin-17 (IL-17) levels than the Caltrate and control groups (all P<0.05). Additionally, PI, PD, GI, and gingival crevicular fluid volume were significantly lower in the XGC group at both time points (all P<0.05). The incidence of adverse reactions did not differ significantly among the three groups (P>0.05).
conclusionXianling Gubao Capsules, when combined with conventional periodontal treatment, may enhance alveolar bone density, reduce alveolar bone defects, alleviate periodontal inflammation, and modulate inflammatory mediator levels in the gingival crevicular fluid. These findings suggest clinical benefits for periodontitis management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.